Interferon-alpha for neurofibromas

Kebudi, Rejin; Ayan, İnci̇

doi:10.1002/(sici)1096-911x(199603)26:3<220::aid-mpo13>3.0.co;2-k

Med. Pediatr. Oncol.

1996

DOI: 10.1002/(sici)1096-911x(199603)26:3<220::aid-mpo13>3.0.co;2-k

|View full text |Cite

Interferon-alpha for neurofibromas

Rejin Kebudi

İnci̇ Ayan

Abstract: A twelve‐year‐old female with neurofibromatosis, presenting with plexiform neurofibromas causing severe pain and in whom relief of pain was achieved after administration of interferon‐alpha, is presented. © 1996 Wiley‐Liss, Inc.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1997

2013

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 9 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with the conclusions of an analysis of NF-1-related trials that the clinical trial design and endpoints used in patients with refractory cancer are not necessarily appropriate for patients with NF1-related tumors. 5 The responsiveness of PN to IFN was first reported in 2006 22 in a child with a PN of the pelvis causing severe pain due to nerve compression. The patient experienced dramatic pain relief within 2 weeks of starting IFN, although no objective decrease in the size of the tumor by standard imaging was seen.…”

mentioning

confidence: 99%

Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas

Jakacki¹,

Dombi²,

Potter³

et al. 2011

Neurology

View full text Add to dashboard Cite

Objective: Interferon has antiproliferative and antiangiogenic properties. We sought to evaluate preliminary efficacy and determine the recommended phase II dose (RP2D) for pegylated interferon-␣-2b (PI) in patients with unresectable progressive or symptomatic plexiform neurofibromas (PN).Methods: PI was administered weekly in cohorts of 3-6 patients during the dose-finding phase and continued for up to 2 years. Twelve patients were treated at the RP2D to further evaluate toxicity and activity.Results: Thirty patients (median age 9.3 years, range 1.9-34.7 years) were enrolled. No doselimiting toxicity (DLT) was seen in patients treated at the 3 g/kg dose level (DL) during the first 4 weeks. All 5 patients treated at the 4.5 g/kg DL came off study or required dose reductions for behavioral toxicity or fatigue. Similar DLT on the 3 g/kg DL became apparent over time. There was 1 DLT (myoclonus) in 12 patients enrolled at the 1.0 g/kg DL. Eleven of 16 patients with pain showed improvement and 13 of 14 patients with a palpable mass had a decrease in size. Five of 17 patients (29%) who underwent volumetric analysis had a 15%-22% decrease in volume. Three of 4 patients with documented radiographic progression prior to enrollment showed stabilization or shrinkage. Conclusions:The RP2D of PI for pediatric patients with PN is 1 g/kg/wk. Clinical and radiographic improvement and cessation of growth can occur. Classification of evidence:This study provides Class III evidence that pegylated interferon-␣-2b in patients with unresectable, progressive, symptomatic, or life-threatening PNs results in radiographic reduction or stabilization of PN size. Neurology ® 2011;76:265-272 GLOSSARY AUC ϭ area under the curve; DL ϭ dose level; DLT ϭ dose-limiting toxicity; FDA ϭ Food and Drug Administration; IFN ϭ interferon; MTD ϭ maximum tolerated dose; NF1 ϭ neurofibromatosis type 1; NHT ϭ nonhematologic toxicity; PEG ϭ polyethylene glycol; PI ϭ pegylated interferon-␣-2b; PN ϭ plexiform neurofibroma; RP2D ϭ recommended phase II dose; STIR ϭ short T1-inversion recovery; TSH ϭ thyroid-stimulating hormone; VA ϭ volumetric analyses.Neurofibromatosis type 1 (NF1) is a common autosomal dominant neurogenetic disorder characterized by a wide variety of progressive cutaneous, neurologic, skeletal, and neoplastic manifestations.1 PN are one of several types of neurofibromas that may occur in patients with NF1 and are characterized by a proliferation of Schwann cells, fibroblasts, and mast cells occurring along the length of a nerve. They occur in 25%-50% of adults and children with NF1, 2,3 and typically infiltrate adjacent normal tissue, making complete surgical resection usually impossible. As they grow, they frequently become disfiguring as well as disabling or even life-threatening. 4,5 Regrowth following subtotal resection is common.6 Standard chemotherapy is not effective and there is currently no standard medical treatment despite various clinical trials. [7][8][9] Interferons (IFNs) have both antiproliferative and antiangiogenic pr...

show abstract

mentioning

confidence: 99%

Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas

Jakacki¹,

Dombi²,

Potter³

et al. 2011

Neurology

View full text Add to dashboard Cite

show abstract

Interferon alfa-2b induced long-term relief of pain in two patients with adiposis dolorosa and chronic hepatitis C

Gonciarz¹,

Mazur²,

Hartleb³

et al. 1997

Journal of Hepatology

View full text Add to dashboard Cite

Management of Plexiform Neurofibroma With Interferon Alpha

Çıtak

Oğuz

Karadeniz

et al. 2008

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Interferon-alpha for neurofibromas

Abstract: A twelve‐year‐old female with neurofibromatosis, presenting with plexiform neurofibromas causing severe pain and in whom relief of pain was achieved after administration of interferon‐alpha, is presented. © 1996 Wiley‐Liss, Inc.

Cited by 5 publications

References 9 publications

Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas

Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas

Interferon alfa-2b induced long-term relief of pain in two patients with adiposis dolorosa and chronic hepatitis C

Management of Plexiform Neurofibroma With Interferon Alpha

Contact Info

Product

Resources

About